Cambridge Healthtech Institute’s 9th Annual
Bioproduction: Scale, Bioreactors & Disposables
Making It Work
August 14-15 , 2019
Cambridge Healthtech Institute’s “Bioproduction” conference reviews the finesse required to manufacture biologics including scale-down models, scaling up production, engineering bioreactors, single-use systems, and ensuring quality within the context of increasing productivity; while ensuring safety and achieving reduced costs. A holistic review of bioprocessing will be explored, as well as practical details, such as monitoring and analyzing processes, and examining in detail how bioreactors process cells and how to keep those cells happy. The conference will address robust production processes and next-generation technologies, while improving manufacturing platforms and ensuring product quality.
Technical Trends and Concepts in Modern Bioprocessing Facilities
Stefan Schmidt, PhD, MBA, COO and Head, Operations, BioAtrium AG
Quality Versus Yield: Trade-Off in Biosimilar Process Development: Lessons Learned
Menzo Havenga, PhD, CEO, Batavia Biosciences
NEXT-GEN STRATEGIES TO IMPROVE PRODUCTION
Process CO2 and Medium Ion Balance Control Strategy for Modulation of Galactosylation and Lactate Metabolism
Woo Suk Ahn, PhD, Scientist, Global Manufacturing Science and Technology (MSAT), Sanofi Genzyme
Development of an In-House Cell Free Extract Process and Robotic Platform for Expression Optimisation
Philip Probert, PhD, Senior Upstream Scientist, Biologics, Centre for Process Innovation (CPI)
MONITORING PROCESSES TO ENSURE QUALITY
Integrating PAT, Data Historian and Automation for Enhancing Process Understanding and Learning
Jean-François Hamel, PhD, Research Engineer, Chemical Engineering, Massachusetts Institute of Technology (MIT)
Online Monitoring of Bioreactors
Jonathan Bones, PhD, Principal Investigator, Characterization and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT)
Bridging Scale-Down Model Learnings with Manufacturing Improvements: A Case Study
Jeremy Discenza, MSc, Associate Scientist II, Bristol-Myers Squibb Co.
SCALING UP PRODUCTION
Cell Line and Process Sensitivities to Hypoxia in Chinese Hamster Ovary Cultures during Bioreactor Scale-Up
Xiaolin Zhang, PhD, Senior Scientist, Merck & Co., Inc.
Efficient Scale-Up and Transfer of Manufacturing Processes
Amit Kumar Srivastava, MTech, Senior Manager, MSAT, Biologics Development Centre, Syngene International, Ltd.
Bench-Scale Single-Use Bioreactor Design and Optimization
T. Craig Seamans, PhD, Senior Principal Scientist, Biologics Process R&D, Merck & Co., Inc.
Disposable Systems for Bioreactor Harvest Clarification
Rustin M. Shenkman, PhD, Senior Development Engineer, Upstream Development Pharmaceutical Sciences (USA), R&D, Takeda Pharmaceutical Company Limited
* The program is subject to change without notice, due to unforeseen reason.